Related Articles
Gene amplification of chromatin remodeling factor <em>SMARCC2</em> and low protein expression of ACTL6A are unfavorable factors in ovarian high‑grade serous carcinoma
Amplification of the NSD3‑BRD4‑CHD8 pathway in pelvic high‑grade serous carcinomas of tubo‑ovarian and endometrial origin
Mutation analysis and genomic imbalances of cells found in effusion fluids from patients with ovarian cancer
TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma
PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports